Avalo Therapeutics (AVTX) Net Cash Flow Growth (5y) (2019 - 2026)
Avalo Therapeutics (AVTX) Net Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.01% |
| Mar 31, 2026 | -13.93% |
| Dec 31, 2025 | 5.12% |
| Sep 30, 2025 | -5.10% |
| Jun 30, 2025 | -32.47% |
| Mar 31, 2025 | -45.34% |
| Dec 31, 2024 | 100.64% |
| Sep 30, 2024 | -22.90% |
| Jun 30, 2024 | -20.08% |
| Mar 31, 2024 | 79.40% |
| Dec 31, 2023 | -22.41% |
| Sep 30, 2023 | -3.83% |
| Jun 30, 2023 | -102.68% |
| Mar 31, 2023 | 123.60% |
| Dec 31, 2022 | 29.04% |
| Sep 30, 2022 | -21.02% |
| Jun 30, 2022 | -67.37% |
| Mar 31, 2022 | -49.98% |
| Dec 31, 2021 | -35.81% |
| Sep 30, 2021 | 64.93% |